Sinopharm Leads $20 Million Investment in Singapore’s Novena; Plans Joint $150 Million Healthcare Fund Life Science
BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor Life Science